Format

Send to

Choose Destination
Vaccine. 2013 Dec 17;32(1):153-8. doi: 10.1016/j.vaccine.2013.08.061. Epub 2013 Sep 7.

Colonisation endpoints in Streptococcus pneumoniae vaccine trials.

Author information

1
Department of Vaccination and Immune Protection, National Institute for Health and Welfare (THL), P.O. BOX 30, FI-00271, Helsinki, Finland. Electronic address: kari.auranen@thl.fi.
2
Department of Vaccination and Immune Protection, National Institute for Health and Welfare (THL), P.O. BOX 30, FI-00271, Helsinki, Finland.
3
University College London Medical School, Institute of Child Health, London, UK.
4
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
5
Pneumococcal Research and Infectious Diseases and Microbiology, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, VIC, Australia; Department of Microbiology and Immunology, The University of Melbourne, Parkville, VIC, Australia.

Abstract

Evaluating vaccine efficacy for protection against colonisation (VEcol) with bacterial pathogens is an area of growing interest. In this article, we consider estimation of VEcol for colonisation with Streptococcus pneumoniae (the pneumococcus). Colonisation is a common, recurrent and multi-type endpoint that requires both careful definition of the vaccine efficacy parameter and the corresponding method of estimation. We review recent developments in the area and provide practical guidelines for choosing the estimand and the estimation method in trials with a colonisation endpoint. We concentrate on methods that are based on a cross-sectional study design, in which only one nasopharyngeal sample is obtained per study subject.

KEYWORDS:

NVT; Nasopharyngeal colonisation; OR; PCV; Pneumococcus; Trial endpoint; VE(T); VE(acq); VE(col); VT; Vaccine efficacy; combined vaccine efficacy against acquisition and duration of colonisation; non-vaccine (sero)type(s); odds ratio; pneumococcal conjugate vaccine; vaccine (sero)type(s); vaccine efficacy against acquisition of colonisation; vaccine efficacy against colonisation

PMID:
24016803
DOI:
10.1016/j.vaccine.2013.08.061
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center